Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas. Show more
Location: 6801 N. Capital of Texas Highway, Austin, TX, 78731, United States | Website: https://www.cassavasciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
106.8M
52 Wk Range
$1.15 - $33.98
Previous Close
$2.21
Open
$2.21
Volume
475,923
Day Range
$2.12 - $2.22
Enterprise Value
-14.13M
Cash
112.4M
Avg Qtr Burn
-23.96M
Insider Ownership
12.79%
Institutional Own.
25.20%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Simufilam Details Tuberous Sclerosis Complex (TSC)-related epilepsy | IND Submission | |
Simufilam (PTI-125) Details Alzheimer's disease | Failed Discontinued |